表紙
市場調查報告書

呼吸疾病用吸入器製造前20名公司分析:2019年

Top 20 Global Respiratory Inhalers Manufacturers 2019: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Merck, Teva, Other Companies

出版商 Visiongain Ltd 商品編碼 862035
出版日期 內容資訊 英文 144 Pages
商品交期: 最快1-2個工作天內
價格
呼吸疾病用吸入器製造前20名公司分析:2019年 Top 20 Global Respiratory Inhalers Manufacturers 2019: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Merck, Teva, Other Companies
出版日期: 2019年04月09日內容資訊: 英文 144 Pages
簡介

全球呼吸疾病用吸入器的市場預計至2023年達380億美元的規模。

本報告提供全球呼吸疾病用吸入器的市場調查,市場及產品概要,市場成長的各種影響因素分析,技術開發趨勢,主要產品,市場佔有率,主要20家公司的企業概要,已上市產品,開發平台趨勢,未來展望等資訊。

第1章 報告概要

第2章 簡介:呼吸疾病用吸入器市場

  • 呼吸疾病用吸入器:概要
    • 噴霧器
    • 定量噴霧吸入器
    • 吸氣感應型加壓噴霧式定量吸入器
    • 加壓噴霧式定量吸入器+墊片設備
    • 乾粉吸入劑 (DPI)
    • 緩霧吸入器
  • COPD用吸入器:概要
    • COPD治療藥
      • 支氣管擴張劑
      • 糖皮質激素
  • 氣喘用吸入器:概要
  • 潛在性、成長推動因素
    • 聯合治療
      • LAMA/LABA並用
      • LABA/ICS並用
      • LABA+LAMA並用 vs LABA+ICS並用
    • 三劑並用
      • LAMA/LABA/ICS三劑並用
  • 市場成長的阻礙要素
  • 技術分析、開發趨勢

第3章 主要產品概要

  • 目前市場
  • 主要企業
  • 市場佔有率的變化預測

第4章 競爭經營者的地位

  • Astrazeneca
  • Glaxosmithkline
  • Boehringer Ingelheim
  • Teva
  • Merck
  • Roche
  • Novartis
  • Mundipharma
  • Pari Medical Holding
  • Omron Healthcare Europe B.V
  • Cipla
  • Sunovion Pharmaceuticals
  • Aerocrine (Circassia)
  • H&T Presspart
  • Beximco Pharmaceuticals Ltd.
  • Chiesi Farmaceutici S.p.A.
  • Pulmatrix
  • Fluidda
  • Pneuma Respiratory
  • Amiko Digital Health
    • 企業概要
    • 已上市產品
    • 開發平台趨勢
    • 未來展望等

第5章 總論

目錄
Product Code: PHA0411

The global respiratory inhalers market is estimated to reach $38bn in 2023. In the respiratory Inhalers market the top three companies by revenue are GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca, with 57.1% of the world market in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 144-page report you will receive 77 charts - all unavailable elsewhere.

The 144-page report provides clear detailed insight into the top 20 global respiratory inhalers manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Top 20 Respiratory Inhalers Market forecasts to 2028

Profiles of the 20 leading respiratory inhalers manufacturers:

  • Aerocrine
  • AMIKO Digital Health
  • AstraZeneca
  • BEXIMCO Pharmaceuticals
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • CIPLA
  • FLUIDDA
  • GlaxoSmithKline
  • H&T Presspart
  • Merck
  • Mundipharma
  • Novartis
  • Omron Healthcare
  • PARI Medical Holding
  • PNEUMA Respiratory
  • PULMATRIX
  • Roche
  • Sunovion Pharmaceuticals
  • Teva

The content of each profile differs, depending on the organization. In general, a profile gives the following information:

  • An overview and analysis of the company
  • A portfolio of the company's marketed product and product pipeline
  • Financial Information
  • Revenue forecast to 2028
  • Recent developments
  • Future Outlook
  • Analysis of the drivers and restraints of the global respiratory inhalers market

Coverage of respiratory inhalers in the R&D pipeline. Discussions of research and development - see progress in this industry, finding technological, clinical and commercial outlooks and opportunities

Key questions Answered by This Report:

  • How is the Respiratory Inhalers Manufacturers market evolving?
  • What is driving and restraining the Respiratory Inhalers Manufacturers market?
  • What will be the main driver for the overall market to 2028?
  • Will leading Respiratory Inhalers Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • Who are the leading players and what are their prospects over the forecast period?

Visiongain's study is intended for anyone requiring commercial analyses for the top 20 global respiratory inhalers manufacturers. You find data, trends and predictions.

Buy our report today Top 20 Global Respiratory Inhalers Manufacturers 2019: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Merck, Teva, Other Companies.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Respiratory Inhalers Manufacturers Market Overview
  • 1.2. Global Respiratory Inhalers Manufacturers Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who Is This Report for?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Respiratory Inhalers

  • 2.1. Respiratory Inhalers Overview
    • 2.1.1. Nebulizers
    • 2.1.2. Metered Dose Inhaler
    • 2.1.3. Breath-Actuated Pressurised Metered-Dose Inhalers
    • 2.1.4. Pressurised Metered-Dose Inhalers Plus Spacer Devices
    • 2.1.5. Dry powder inhalers (DPIs)
    • 2.1.6. Soft Mist Inhalers
  • 2.2. COPD Respiratory Inhalers Overview
    • 2.2.1. Chronic Obstructive Pulmonary Disease Medications
      • 2.2.1.1. Bronchodilators
      • 2.2.1.2. Glucocorticoids
  • 2.3. Asthma Respiratory Inhalers Overview
    • 2.3.1. Desirable inhaler characteristics for treating asthma
  • 2.4. Respiratory Inhalers - Realising Their Potential, Market Drivers
    • 2.4.1. Combination Therapies - Respiratory Inhalers
      • 2.4.1.1. LAMA/LABA combinations
      • 2.4.1.2. LABA/ICS combination
      • 2.4.1.3. LABA+LAMA vs. LABA+ICS combinations
    • 2.4.2. Triple Combination - Respiratory Inhalers
      • 2.4.2.1. LAMA/LABA/ICS “triple combination inhalers”
  • 2.5. Market Restraints
  • 2.6. Respiratory Inhalers: Trends and Developments
    • 2.6.1. E-Technology in Asthma and COPD

3. Leading Respiratory Inhalers Products: Overview, 2018

  • 3.1. The Global Respiratory Inhalers Market In 2018
  • 3.2. Leading Companies in the Respiratory Inhalers Market, 2018
  • 3.3. How Will Leading Companies' Market Shares Change to 2028?

4. Leading Respiratory Inhalers Manufacturers Worldwide, 2018

  • 4.1. Astrazeneca - Company Overview & Analysis
    • 4.1.1. AstraZeneca Marketed Respiratory Inhalers
      • 4.1.1.1. Latest developments related to Key Marketed Products
        • 4.1.1.1.1. Symbicort: Recent Developments
        • 4.1.1.1.2. Bevespi Aerosphere: Recent Developments
        • 4.1.1.1.3. Tudorza/ Eklira Genuair: Recent Developments
        • 4.1.1.1.4. Duaklir: Recent Developments
        • 4.1.1.1.5. Fasenra: Recent Developments
        • 4.1.1.1.6. Other Recent Developments
    • 4.1.2. AstraZeneca Respiratory Inhalers R&D Pipeline & Future Outlook
      • 4.1.2.1. Latest developments related to Key Pipeline Products
        • 4.1.2.1.1. PT010/ PT009/ PT008/ PT005: Pipeline Developments
        • 4.1.2.1.2. Fasenra: Pipeline Developments
        • 4.1.2.1.3. Tezepelumab: Pipeline Developments
        • 4.1.2.1.4. Tralokinumab: Pipeline Developments
    • 4.1.3. AstraZeneca Respiratory Market Forecast, 2017-2028
  • 4.2. Glaxosmithkline - Company Overview & Analysis
    • 4.2.1. GlaxoSmithKline Marketed Respiratory Inhalers
      • 4.2.1.1. Latest Developments related to Key Marketed Products
        • 4.2.1.1.1. Relvar/Breo Ellipta: Recent Developments
        • 4.2.1.1.2. Anoro Ellipta: Recent Developments
        • 4.2.1.1.3. Nucala: Recent Developments
        • 4.2.1.1.4. Seretide/Advair: Recent Developments
        • 4.2.1.1.5. Trelegy Ellipta: Recent Developments
        • 4.2.1.1.6. Breo Ellipta, Advair Diskus and Advair HFA: Recent Developments
    • 4.2.2. GlaxoSmithKline Respiratory Inhalers R&D Pipeline & Future Outlook
      • 4.2.2.1. Latest developments related to Key Pipeline Products
        • 4.2.2.1.1. Nucala: Recent Developments
    • 4.2.3. GlaxoSmithKline Respiratory Market Forecast, 2017-2028
  • 4.3. Boehringer Ingelheim - Company Overview & Analysis
    • 4.3.1. Boehringer Ingelheim Marketed Respiratory Inhalers
      • 4.3.1.1. Latest Developments related to Key Marketed Products
        • 4.3.1.1.1. Spiriva Respimat: Recent Developments
        • 4.3.1.1.1. Spiolto Respimat: Recent Developments
        • 4.3.1.1.2. Ofev: Recent Developments
    • 4.3.2. Boehringer Ingelheim Respiratory Inhalers R&D Pipeline & Future Outlook
    • 4.3.3. Boehringer Ingelheim Respiratory Market Forecast, 2017-2028
  • 4.4. Teva - Company Overview & Analysis
    • 4.4.1. Teva Marketed Respiratory Inhalers
      • 4.4.1.1. Latest developments related to Key Marketed Products
        • 4.4.1.1.1. QVAR: Recent Developments
        • 4.4.1.1.2. ProAir HFA: Recent Development
        • 4.4.1.1.3. DuoResp Spiromax: Recent Developments
        • 4.4.1.1.4. Aerivio Spiromax: Recent Developments
        • 4.4.1.1.5. CINQAIR/CINQAERO: Recent Developments
        • 4.4.1.1.6. AirDuo RespiClick / ArmonAir RespiClick: Recent Development
    • 4.4.2. Teva Respiratory Inhalers R&D Pipeline & Future Outlook
      • 4.4.2.1. Latest developments related to Key Pipeline Products
        • 4.4.2.1.1. ProAir e-RespiClick: Recent Developments
    • 4.4.3. Teva Respiratory Market Forecast, 2017-2028
  • 4.5. Merck - Company Overview & Analysis
    • 4.5.1. Merck Marketed Respiratory Inhalers
      • 4.5.1.1. Latest Developments related to Key Marketed Products
        • 4.5.1.1.1. Dulera: Recent Development
    • 4.5.2. Merck Respiratory Inhalers R&D Pipeline & Future Outlook
    • 4.5.3. Merck Respiratory Market Forecast, 2017-2028
  • 4.6. Roche - Company Overview & Analysis
    • 4.6.1. Roche Marketed Respiratory Inhalers
      • 4.6.1.1. Latest Developments related to Key Marketed Products
        • 4.6.1.1.1. Xolair: Recent Developments
    • 4.6.2. Roche Respiratory Inhalers R&D Pipeline & Future Outlook
      • 4.6.2.1. Latest Developments related to Key Pipeline Products
        • 4.6.2.1.1. RG3637: Pipeline Developments
    • 4.6.3. Roche Respiratory Market Forecast, 2017-2028
  • 4.7. Novartis - Company Overview & Analysis
    • 4.7.1. Novartis Marketed Respiratory Inhalers
      • 4.7.1.1. Latest developments related to Key Marketed Products
        • 4.7.1.1.1. Ultibro Breezhaler: Recent Developments
        • 4.7.1.1.2. Xolair: Recent Developments
    • 4.7.2. Novartis Respiratory Inhalers R&D Pipeline & Future Outlook
      • 4.7.2.1. Latest developments related to Key Pipeline Products
        • 4.7.2.1.1. QAW039: Pipeline Developments
        • 4.7.2.1.2. QBW251: Pipeline Developments
        • 4.7.2.1.3. QVM149: Pipeline Developments
        • 4.7.2.1.4. CSJ117: Pipeline Developments
        • 4.7.2.1.5. CJM112: Pipeline Developments
    • 4.7.3. Novartis Respiratory Market Forecast, 2017-2028
  • 4.8. Mundipharma - Company Overview & Analysis
    • 4.8.1. Mundipharma Marketed Respiratory Inhalers
      • 4.8.1.1. Latest Developments related to Key Marketed Products
        • 4.8.1.1.1. Flutiform (fluticasone propionate and formoterol): Recent Developments
        • 4.8.1.1.2. Company Related Developments
    • 4.8.2. Mundipharma Respiratory Inhalers R&D Pipeline & Future Outlook
      • 4.8.2.1. Latest Developments related to Key Pipeline Products
        • 4.8.2.1.1. Flutiform k-haler (fluticasone propionate and formoterol): Recent Developments
  • 4.9. Pari Medical Holding - Company Overview & Analysis
    • 4.9.1. PARI Medical Holding Marketed Respiratory Inhalers
      • 4.9.1.1. Latest Developments related to Key Marketed Products
        • 4.9.1.1.1. SUN-101: Recent Developments
    • 4.9.2. PARI Pharma Respiratory Inhalers R&D Pipeline & Future Outlook
      • 4.9.2.1. Latest Developments related to Key Pipeline Products
        • 4.9.2.1.1. Cyclosporin A: Recent Developments
  • 4.10. Omron Healthcare Europe B.V- Company Overview & Analysis
    • 4.10.1. Omron Healthcare Europe B.V: Marketed Respiratory Products
      • 4.10.1.1. Latest Developments related to Company
        • 4.10.1.1.1. Company Recent Developments
  • 4.11. Cipla- Company Overview & Analysis
    • 4.11.1. Cipla Marketed Respiratory Inhalers
      • 4.11.1.1. Latest Developments related to Key Marketed Products
        • 4.11.1.1.1. Budesonide Inhalation Suspension: Pipeline Developments
        • 4.11.1.1.2. SynchroBreathe: Pipeline Developments
      • 4.11.1.2. Cipla Launch Plans for Respiratory Products
  • 4.12. Sunovion Pharmaceuticals- Company Overview & Analysis
    • 4.12.1. Sunovion Pharmaceuticals: Marketed Respiratory Inhalers
      • 4.12.1.1. Latest Developments related to Key Marketed Products
        • 4.12.1.1.1. SUN-101: Recent Developments
    • 4.12.2. Sunovion Pharmaceuticals Respiratory Inhalers R&D Pipeline & Future Outlook
    • 4.12.3. Sunovion Respiratory Market Forecast, 2017-2028
  • 4.13. Aerocrine (Circassia)- Company Overview & Analysis
    • 4.13.1. Circassia Marketed Respiratory Inhalers
      • 4.13.1.1. Latest Developments related to Key Marketed Products
        • 4.13.1.1.1. NIOX: Recent Developments
        • 4.13.1.1.2. Tudorza Pressair: Recent Developments
    • 4.13.2. Circassia Respiratory Inhalers R&D Pipeline & Future Outlook
      • 4.13.2.1. Latest Developments related to Key Pipeline Products
        • 4.13.2.1.1. Duaklir Pressair US: Pipeline Developments
    • 4.13.3. Circassia Respiratory Market Forecast, 2017-2028
  • 4.14. H&T Presspart - Company Overview & Analysis
    • 4.14.1. H&T Presspart Marketed Respiratory Inhalers
      • 4.14.1.1. Latest Developments related to the Company
        • 4.14.1.1.1. Recent Developments
    • 4.14.2. H&T Presspart Respiratory Inhalers R&D Pipeline & Future Outlook
    • 4.14.3. H&T Presspart Respiratory Market Forecast, 2017-2028
  • 4.15. Beximco Pharmaceuticals Ltd.- Company Overview & Analysis
    • 4.15.1. Beximco Pharmaceuticals Marketed Respiratory Inhalers
    • 4.15.2. Beximco Respiratory Inhalers R&D Pipeline & Future Outlook
    • 4.15.3. Beximco Respiratory Market Forecast, 2017-2028
  • 4.16. Chiesi Farmaceutici S.p.A. - Company Overview & Analysis
    • 4.16.1. Chiesi Farmaceutici S.p.A Marketed Respiratory Inhalers
      • 4.16.1.1. Latest Developments related to Key Marketed Products
        • 4.16.1.1.1. Trimbow: Recent Developments
    • 4.16.2. Chiesi Farmaceutici Respiratory Inhalers R&D Pipeline & Future Outlook
      • 4.16.2.1. Latest Developments related to Key Pipeline Products
        • 4.16.2.1.1. Bronchitol: Recent development
        • 4.16.2.1.2. CHF 6297: Recent development
    • 4.16.3. Chiesi Farmaceutici: Respiratory Market Forecast, 2017-2028
  • 4.17. Pulmatrix: Company Overview & Analysis
    • 4.17.1. Pulmatrix Respiratory Inhalers R&D Pipeline & Future Outlook
      • 4.17.1.1. Latest Developments related to Key Pipeline Products
        • 4.17.1.1.1. PUR0200-US: Recent development
        • 4.17.1.1.2. PUR1900: Recent development
  • 4.18. Fluidda- Company Overview & Analysis
    • 4.18.1. Latest Developments related to the Company
  • 4.19. Pneuma Respiratory - Company Overview & Analysis
    • 4.19.1. Latest Developments related to the Company
  • 4.20. Amiko Digital Health- Company Overview & Analysis
    • 4.20.1. Amiko Digital Health Marketed Respiratory Inhaler Product

5. Conclusions

  • 5.1. Respiratory Inhalers: A Maturing Market
  • 5.2. The Global Respiratory Inhalers Manufacturers Market In 2018
  • 5.3. Leading Respiratory Inhalers Companies
  • 5.4. Global Respiratory Inhalers Market Forecast 2017-2028
  • 5.5. The Future of the Respiratory Inhalers Market
    • 5.5.1. Growth in Anti-Inflammatory and Combination Drugs
    • 5.5.2. Personalised Medicine
    • 5.5.3. Unmet Needs in Asthma and COPD
  • 5.6. Strategies for Growth In 2018-2028

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • TABLE 2.1: ADVANTAGES AND DISADVANTAGES OF THE MAIN TYPES OF ASTHMA INHALERS
  • TABLE 2.2: E-TECHNOLOGY BASED INHALERS
  • TABLE 3.1: GLOBAL MARKET FORECASTS: REVENUES ($BN), AGR (%) AND CAGR (%), BY LEADING COMPANIES, 2017-2028
  • TABLE 3.2: LEADING COMPANIES IN RESPIRATORY INHALERS
  • TABLE 3.3: LEADING RESPIRATORY INHALERS MANUFACTURERS: REVENUES ($BN) AND MARKET SHARES (%), 2018 AND 2028
  • TABLE 4.1: ASTRAZENECA: COMPANY OVERVIEW, 2018
  • TABLE 4.2: ASTRAZENECA: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.3: ASTRAZENECA: PRODUCTS PIPELINE PORTFOLIO, 2018
  • TABLE 4.4: ASTRAZENECA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
  • TABLE 4.5: GLAXOSMITHKLINE: COMPANY OVERVIEW, 2018
  • TABLE 4.6: GLAXOSMITHKLINE: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.7: GLAXOSMITHKLINE: PRODUCTS PIPELINE PORTFOLIO, 2018
  • TABLE 4.8: GLAXOSMITHKLINE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
  • TABLE 4.9: BOEHRINGER INGELHEIM: COMPANY OVERVIEW, 2018
  • TABLE 4.10: BOEHRINGER INGELHEIM: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.11: BOEHRINGER INGELHEIM: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
  • TABLE 4.12: TEVA: COMPANY OVERVIEW, 2018
  • TABLE 4.13: TEVA: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.14: TEVA: PRODUCTS PIPELINE PORTFOLIO, 2018
  • TABLE 4.15: TEVA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
  • TABLE 4.16: MERCK: COMPANY OVERVIEW, 2018
  • TABLE 4.17: MERCK: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.18: MERCK: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
  • TABLE 4.19: ROCHE: COMPANY OVERVIEW, 2018
  • TABLE 4.20: ROCHE: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.21: ROCHE: PRODUCTS PIPELINE PORTFOLIO, 2018
  • TABLE 4.22: ROCHE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
  • TABLE 4.23: NOVARTIS: COMPANY OVERVIEW, 2018
  • TABLE 4.24: NOVARTIS: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.25: NOVARTIS: PRODUCTS PIPELINE PORTFOLIO, 2018
  • TABLE 4.26: NOVARTIS: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
  • TABLE 4.27: MUNDIPHARMA: COMPANY OVERVIEW, 2018
  • TABLE 4.28: MUNDIPHARMA: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.29: MUNDIPHARMA: PRODUCTS PIPELINE PORTFOLIO, 2018
  • TABLE 4.30: PARI MEDICAL HOLDING: COMPANY OVERVIEW, 2018
  • TABLE 4.31: PARI MEDICAL HOLDING: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.32: PARI MEDICAL HOLDING: PRODUCTS PIPELINE PORTFOLIO, 2018
  • TABLE 4.33: OMRON HEALTHCARE EUROPE B.V: COMPANY OVERVIEW, 2018
  • TABLE 4.34: OMRON HEALTHCARE EUROPE B.V: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.35: CIPLA: COMPANY OVERVIEW, 2018
  • TABLE 4.36: CIPLA: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.37: SUNOVION PHARMACEUTICALS: COMPANY OVERVIEW, 2018
  • TABLE 4.38: SUNOVION PHARMACEUTICALS: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.39: SUNOVION: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
  • TABLE 4.40: CIRCASSIA: COMPANY OVERVIEW, 2018
  • TABLE 4.41: CIRCASSIA: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.42: CIRCASSIA: PRODUCTS PIPELINE PORTFOLIO, 2018
  • TABLE 4.43: H&T PRESSPART: COMPANY OVERVIEW, 2018
  • TABLE 4.44: H&T PRESSPART: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.45: BEXIMCO PHARMACEUTICALS: COMPANY OVERVIEW, 2018
  • TABLE 4.46: BEXIMCO PHARMACEUTICALS: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.47: CHIESI FARMACEUTICI S.P.A: COMPANY OVERVIEW, 2018
  • TABLE 4.48: CHIESI FARMACEUTICI S.P.A: PRODUCTS PORTFOLIO, 2018
  • TABLE 4.49: CHIESI FARMACEUTICI S.P.A: PRODUCTS PIPELINE PORTFOLIO, 2018
  • TABLE 4.50: CHIESI FARMACEUTICI S.P.A: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
  • TABLE 4.51: PULMATRIX: COMPANY OVERVIEW, 2018
  • TABLE 4.52: PULMATRIX: PRODUCTS PIPELINE PORTFOLIO, 2018
  • TABLE 4.53: FLUIDDA: COMPANY OVERVIEW, 2018
  • TABLE 4.54: PNEUMA RESPIRATORY: COMPANY OVERVIEW, 2018
  • TABLE 4.55: AMIKO DIGITAL HEALTH: COMPANY OVERVIEW, 2018

List of Figures

  • FIGURE 1.1: GLOBAL RESPIRATORY INHALERS MANUFACTURERS MARKET SEGMENTATION OVERVIEW, 2018
  • FIGURE 2.1: STEPWISE APPROACH TO TREATMENT OF COPD
  • FIGURE 3.1: GLOBAL: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
  • FIGURE 3.2: LEADING RESPIRATORY MANUFACTURERS: REVENUE ($BN), 2018
  • FIGURE 3.3: LEADING RESPIRATORY MANUFACTURERS: MARKET SHARE (%), 2018
  • FIGURE 3.4: LEADING RESPIRATORY INHALERS MANUFACTURERS: REVENUES ($M), 2028
  • FIGURE 3.5: LEADING RESPIRATORY INHALERS MANUFACTURERS: MARKET SHARES (%), 2028
  • FIGURE 4.1: ASTRAZENECA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
  • FIGURE 4.2: GLAXOSMITHKLINE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
  • FIGURE 4.3: BOEHRINGER INGELHEIM: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
  • FIGURE 4.4: TEVA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
  • FIGURE 4.5: MERCK: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
  • FIGURE 4.6: ROCHE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
  • FIGURE 4.7: NOVARTIS: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
  • FIGURE 4.8: SUNOVION RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
  • FIGURE 4.9: CHIESI FARMACEUTICI RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
  • FIGURE 5.1: WORLD RESPIRATORY INHALERS MARKET FORECAST: REVENUES ($M), 2017-2028

COMPANIES LISTED:

  • 3A Health Care s.r.l.
  • 3M Pharmaceuticals
  • Aerocrine (Circassia)
  • Aerocrine AB
  • Amgen
  • Amiko Digital Health
  • AstraZeneca
  • Beximco Pharmaceuticals Limited (Beximco Pharma)
  • BioCare Manufacturing Malaysia
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Ciba-Geigy
  • Cipla Ltd.
  • Circassia Pharmaceuticals
  • Cree
  • Dainippon Sumitomo Pharma America, Inc.
  • Dermira Inc.
  • EasibreatheTM
  • Fluidda
  • Genentech
  • General Electric
  • GlaxoSmithKline
  • Glenmark
  • H&T Presspart
  • Heitkamp & Thumann KG
  • Heitkamp and Thumann Group
  • Hovione Technology
  • Innoviva, Inc.
  • Meda
  • Merck
  • MundiPharma
  • Novartis
  • OMRON Healthcare Europe B.V.
  • OMRON Healthcare Group
  • Pari Medical Holding
  • PARI Pharma GmbH
  • Perrigo
  • Pfizer
  • Philips
  • Pneuma Respiratory, Inc.
  • Presspart Manufacturing Limited
  • Pulmatrix, Inc.
  • Roche
  • Sandoz
  • Sepracor Inc.
  • Sorrento
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Sunovion Pharmaceuticals Inc.
  • Teva
  • Vectura
  • Vizient, Inc.

List of Organizations Mentioned in the Report:

  • European Commission
  • European Medicines Agency (EMA)
  • European Respiratory Society (ERS)
  • Food and Drug Administration (FDA)
  • Japanese Ministry of Health
  • National Institute for Health and Care Excellence (NICE
  • United States Patent and Trademark Office (USPTO)
  • University of Maryland